WILMINGTON, Mass., Dec. 23, 2014 /PRNewswire/ -- Implant
Sciences Corporation (OTCQB: IMSC), a high technology supplier of
systems and sensors for homeland security and defense markets,
announced today its QS-B220 desktop explosives and drugs trace
detector has received approval from the Civil Aviation
Administration of China
(CAAC).
"We are proud to have received approval for the QS-B220 from
CAAC, which is the equivalent of the TSA in the United States. China has traditionally been a very strong
market for us, with hundreds of our trace detection systems being
currently used by police, airports, and subways. We believe our
reputation for quality and performance will translate into
significant QS-B220 sales in the Chinese market," stated Implant
Sciences' CEO, Glenn D. Bolduc. "The
QS-B220 is the only trace ETD in the world to currently have passed
testing by the TSA in the United
States, ECAC in Europe, and
CAAC in China."
146 airports in China recently received $196 million in
subsidies from the Civil Aviation Administration of China earlier in December 2014. According to the Chinese
government's 12th five-year plan, the total number of airports is
set to expand from 175 in 2010 to 230 in 2015.
About the QS-B220 Desktop Explosives and Drugs Trace
Detector
The QS-B220 uses Ion Mobility Spectrometry (IMS) to rapidly
detect and identify trace amounts of a wide variety of military,
commercial, and homemade explosives as well as illicit drugs. With
significantly lower maintenance requirements than competing
systems, the QS-B220 can be deployed for a much lower total cost of
ownership than other approved products. Featuring a radioactive
material-free design, push-button maintenance and diagnostics, and
a patented inCal™ internal automatic calibration system, the
QS-B220 brings new levels of performance and convenience to desktop
trace detection users with unsurpassed ease of use.
About Implant Sciences
Implant Sciences is a leader in developing and manufacturing
advanced detection capabilities to counter and eliminate the
ever-evolving threats from explosives and drugs. The Company's team
of dedicated trace detection experts has developed proprietary
technologies used in its commercial products, thousands of which
have been sold across more than 50 countries worldwide. Implant
Sciences is only the third manufacturer, and the sole
American-owned company, to currently have an ETD system named as a
Qualified Product by the US Transportation Security Administration.
The Company's ETDs have received approvals and certifications from
several international regulatory agencies including the TSA in the
U.S., ECAC in Europe, CAAC and the
Ministry of Public Safety in China, STAC in France, and the German Ministry of the
Interior. It has also received the GSN Homeland Security Award for
"Best Explosives Detection Solution" two years in a row (2013 and
2014). All Implant Sciences products are recognized as
Qualified Anti-Terrorism Technologies by the Department of Homeland
Security. For further details on the Company and its products,
please visit the Company's website at www.implantsciences.com.
Safe Harbor Statement
This press release may contain certain "forward-looking
statements," as that term is defined in the Private Securities
Litigation Reform Act of 1995. Such statements are based on
management's current expectations and are subject to risks and
uncertainties that could cause the Company's actual results to
differ materially from the forward-looking statements. Such risks
and uncertainties include, but are not limited to, the risks that
we will be required to repay all of our indebtedness to our secured
lenders by March 31, 2015; if we are
unable to satisfy our obligations to our secured lenders and to
raise additional capital to fund operations, our lenders may seize
our assets and our business may fail; we continue to incur
substantial operating losses and may never be profitable; our
independent registered public accounting firm has expressed
substantial doubt as to our ability to continue as a going concern;
there is no guaranty that the Transportation Security
Administration (TSA) or any other U.S. or foreign government and
law enforcement agencies or commercial consumers will purchase any
of our explosives detection products or that any new products we
may develop will be accepted by the TSA or by such other
governments, agencies or consumers; economic, political and other
risks associated with international sales and operations could
adversely affect our sales; liability claims related to our
products or our handling of hazardous materials could damage our
reputation and have a material adverse effect on our financial
results; our business is subject to intense competition; our
markets are subject to rapid technology change and our success will
depend on our ability to develop and introduce new products; we may
not be able to retain our management and key employees or identify,
hire and retain additional personnel as needed; we may not be able
to enforce our patent and other intellectual property rights or
operate without infringing on the proprietary rights of others; and
other risks and uncertainties described in our filings with the
Securities and Exchange Commission, including our most recent Forms
10-K, 10-Q and 8-K. Such statements are based on management's
current expectations and assumptions which could differ materially
from the forward-looking statements.
Contact:
Implant Sciences Corporation
Company Contact:
Glenn Bolduc, CEO
978-752-1700
or
Investor Contact:
Laurel Moody
646-810-0608
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/implant-sciences-qs-b220-receives-regulatory-approval-for-china-airports-and-civil-aviation-industry-300013637.html
SOURCE Implant Sciences Corporation